

# Meg J Jardine

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2471302/publications.pdf>

Version: 2024-02-01

186  
papers

14,958  
citations

31902

53  
h-index

19690

117  
g-index

200  
all docs

200  
docs citations

200  
times ranked

14634  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. <i>American Journal of Kidney Diseases</i> , 2022, 79, 244-256.e1.   | 2.1 | 23        |
| 2  | Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial. <i>Journal of Diabetes Investigation</i> , 2022, 13, 54-64. | 1.1 | 11        |
| 3  | GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes. <i>Kidney International</i> , 2022, 101, 360-368.   | 2.6 | 15        |
| 4  | Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 361-373.  | 2.2 | 9         |
| 5  | Sex differences in chronic kidney disease prevalence in Asia: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1144-1151.   | 1.4 | 5         |
| 6  | The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. <i>Diabetes and Metabolism</i> , 2022, 48, 101331.   | 1.4 | 5         |
| 7  | SGLT2 inhibitors may prevent diabetes. <i>Nature Reviews Nephrology</i> , 2022, 18, 203-204.  | 4.1 | 4         |
| 8  | Antiplatelet agents for chronic kidney disease. <i>The Cochrane Library</i> , 2022, 2022, CD008834.   | 1.5 | 6         |
| 9  | SGLT2 inhibitors and finerenone: one or the other or both?. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1209-1211.   | 0.4 | 9         |
| 10 | Prior Cardiovascular Treatmentsâ€”A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction. <i>Frontiers in Pharmacology</i> , 2022, 13, 834898.   | 1.6 | 1         |
| 11 | Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 665-673.  | 3.0 | 4         |
| 12 | A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 840611.  | 1.1 | 0         |
| 13 | Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to Action. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812210803.   | 0.6 | 5         |
| 14 | Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.  | 3.8 | 103       |
| 15 | Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-12.  | 1.0 | 3         |
| 16 | An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , 2021, 324, 165-172.  | 0.8 | 6         |
| 17 | Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazoleâ€”trimethoprim and temozolomide. <i>Nephrology</i> , 2021, 26, 12-14.   | 0.7 | 2         |
| 18 | <sc>Sodiumâ€”glucose coâ€”transporterâ€”2</sc> inhibitors with and without metformin: A metaâ€”analysis of cardiovascular, kidney and mortality outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 382-390.  | 2.2 | 40        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 763-773.   | 2.2 | 12        |
| 20 | Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. <i>American Journal of Kidney Diseases</i> , 2021, 77, 23-34.e1.                                     | 2.1 | 38        |
| 21 | Innovating and invigorating the clinical trial infrastructure for glomerular diseases. <i>Kidney International</i> , 2021, 99, 519-523.   | 2.6 | 4         |
| 22 | Insights from CRENDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021, 99, 999-1009.   | 2.6 | 93        |
| 23 | The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals. <i>Kidney International</i> , 2021, 99, 551-554.  | 2.6 | 2         |
| 24 | Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor. <i>Kidney International Reports</i> , 2021, 6, 284-295.  | 0.4 | 8         |
| 25 | SGLT2 inhibitors may offer benefit beyond diabetes. <i>Nature Reviews Nephrology</i> , 2021, 17, 83-84.   | 4.1 | 29        |
| 26 | Sodium-glucose cotransporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 252-257.   | 2.2 | 12        |
| 27 | Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. <i>ESC Heart Failure</i> , 2021, 8, 1482-1493.  | 1.4 | 16        |
| 28 | Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 384-395.   | 2.2 | 37        |
| 29 | Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1420-1425.   | 2.2 | 3         |
| 30 | Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis. <i>Hemodialysis International</i> , 2021, 25, 322-332.   | 0.4 | 10        |
| 31 | Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus. <i>Metabolism: Clinical and Experimental</i> , 2021, 116, 154509.  | 1.5 | 0         |
| 32 | Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CRENDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148. | 1.2 | 30        |
| 33 | Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00247.   | 1.0 | 5         |
| 34 | Cloth Masks May Prevent Transmission of COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 580.  | 2.0 | 1         |
| 35 | The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CRENDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1652-1659.   | 2.2 | 6         |
| 36 | Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis. <i>Kidney International Reports</i> , 2021, 6, 1058-1065.   | 0.4 | 3         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1735-1749.   | 1.6 | 60        |
| 38 | Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. <i>Stroke</i> , 2021, 52, 1545-1556.   | 1.0 | 60        |
| 39 | 129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial. <i>Diabetes</i> , 2021, 70, 129-LB.  | 0.3 | 0         |
| 40 | 133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE. <i>Diabetes</i> , 2021, 70, 133-LB.  | 0.3 | 0         |
| 41 | 131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial. <i>Diabetes</i> , 2021, 70, 131-LB.  | 0.3 | 0         |
| 42 | Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1365-1375.   | 2.2 | 10        |
| 43 | Reasons for hospitalizations in patients with type 2 diabetes in the <scp>CANVAS</scp> programme: A secondary analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2707-2715.  | 2.2 | 6         |
| 44 | Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021, 42, 4891-4901.  | 1.0 | 80        |
| 45 | Protocol for the Controlled evaluation of Angiotensin Receptor blockers for COVID-19 respiratory disease (CLARITY): a randomised controlled trial. <i>Trials</i> , 2021, 22, 573.   | 0.7 | 7         |
| 46 | Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. <i>Diabetologia</i> , 2021, 64, 2402-2414. | 2.9 | 6         |
| 47 | The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021, 52, 827-836.   | 1.4 | 15        |
| 48 | Impact of supplemental private health insurance on dialysis and outcomes. <i>Internal Medicine Journal</i> , 2020, 50, 542-549.   | 0.5 | 3         |
| 49 | Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.  | 2.6 | 260       |
| 50 | Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <math>\geq 7\%</math>. <i>Circulation</i> , 2020, 141, 407-410.           | 1.6 | 95        |
| 51 | Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 903-914.  | 5.5 | 73        |
| 52 | Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2925-2936.  | 3.0 | 82        |
| 53 | International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.   | 2.6 | 65        |
| 54 | Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1129-1138.   | 2.2 | 5         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Effects of Canagliflozin in Patients with Baseline eGFR <math>\leq 30\text{ ml/min per }1.73\text{ m}^2</math>. <i>Clinical Journal of the American Society of Nephrology</i> : CJASN, 2020, 15, 1705-1714.                                   | 2.2 | 87        |
| 56 | Prevalence, incidence and risk factors of diabetes in Australian adults aged <math>\geq 45</math> years: A cohort study using linked routinely-collected data. <i>Journal of Clinical and Translational Endocrinology</i> , 2020, 22, 100240. | 1.0 | 6         |
| 57 | How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 823-836.  | 0.9 | 1         |
| 58 | Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CRENDENCE. <i>Journal of Nephrology</i> , 2020, 33, 977-983.   | 0.9 | 2         |
| 59 | Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth Masks—A Narrative Review. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2204-2224.   | 1.4 | 46        |
| 60 | Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning. <i>Journal of Cardiac Failure</i> , 2020, 26, 1028-1029.  | 0.7 | 0         |
| 61 | A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). <i>Journal of the American Society of Nephrology</i> : JASN, 2020, 31, 2653-2666.  | 3.0 | 52        |
| 62 | Therapy Escalation Following an Elevated HbA1c in Adults Aged 45 Years and Older Living With Diabetes in Australia: A Real-World Observational Analysis. <i>Diabetes Care</i> , 2020, 43, e185-e187.  | 4.3 | 1         |
| 63 | Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CRENDENCE Randomized Trial. <i>Journal of the American Society of Nephrology</i> : JASN, 2020, 31, 1128-1139.            | 3.0 | 106       |
| 64 | EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CRENDENCE TRIAL. <i>Journal of the American College of Cardiology</i> , 2020, 75, 215.  | 1.2 | 2         |
| 65 | The effect of canagliflozin on amputation risk in the <sc>CANVAS</sc> program and the <sc>CRENDENCE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1753-1766.  | 2.2 | 31        |
| 66 | The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. <i>International Journal of Cardiology</i> , 2020, 318, 126-129.          | 0.8 | 18        |
| 67 | No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial. <i>Nephrology</i> , 2020, 25, 792-800.  | 0.7 | 3         |
| 68 | Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020, 76, 109-120.  | 2.1 | 10        |
| 69 | Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study. <i>Diabetes Care</i> , 2020, 43, 982-990.  | 4.3 | 15        |
| 70 | EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION. <i>Journal of the American College of Cardiology</i> , 2020, 75, 221.   | 1.2 | 1         |
| 71 | Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1761-1769.            | 0.4 | 5         |
| 72 | A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study. <i>Blood Purification</i> , 2020, 49, 468-478.   | 0.9 | 38        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Sodium-glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e014908. | 1.6 | 161       |
| 74 | Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CRENDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 46-54.  | 2.2 | 36        |
| 75 | Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis. <i>Journal of Cardiac Failure</i> , 2020, 26, 482-491.  | 0.7 | 8         |
| 76 | Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, i48-i55.   | 0.4 | 18        |
| 77 | Examining Outcomes in Chronic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study. <i>JMIR Research Protocols</i> , 2020, 9, e15646.   | 0.5 | 9         |
| 78 | 27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Diabetes</i> , 2020, 69, .  | 0.3 | 2         |
| 79 | Cloth Masks May Prevent Transmission of COVID-19: An Evidence-Based, Risk-Based Approach. <i>Annals of Internal Medicine</i> , 2020, 173, 489-491.   | 2.0 | 68        |
| 80 | 1098-P: Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial. <i>Diabetes</i> , 2020, 69, .   | 0.3 | 0         |
| 81 | 1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD). <i>Diabetes</i> , 2020, 69, .   | 0.3 | 0         |
| 82 | 26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CRENDENCE. <i>Diabetes</i> , 2020, 69, .   | 0.3 | 0         |
| 83 | Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 quality of life: An AusDiab analysis. <i>Nephrology</i> , 2019, 24, 605-614.             | 0.7 | 10        |
| 84 | Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. <i>Diabetologia</i> , 2019, 62, 1854-1867.   | 2.9 | 58        |
| 85 | Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.                               | 1.6 | 211       |
| 86 | Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study. <i>BMC Nephrology</i> , 2019, 20, 258.  | 0.8 | 7         |
| 87 | Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease. <i>JAMA Internal Medicine</i> , 2019, 179, 1316.  | 2.6 | 52        |
| 88 | Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. <i>Cmaj</i> , 2019, 191, E1128-E1135.  | 0.9 | 17        |
| 89 | SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 845-854.  | 5.5 | 595       |
| 90 | Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 836-849.   | 2.6 | 80        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 91  | Chronic Kidney Disease and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1823-1838.  | 1.2  | 403       |
| 92  | Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1237-1250.  | 2.2  | 190       |
| 93  | Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol. <i>BMJ Open</i> , 2019, 9, e023736.   | 0.8  | 8         |
| 94  | Ethical Issues in Pragmatic Cluster-Randomized Trials in Dialysis Facilities. <i>American Journal of Kidney Diseases</i> , 2019, 74, 659-666.  | 2.1  | 6         |
| 95  | Cardiovascular adaptations associated with exercise in patients on hemodialysis. <i>Seminars in Dialysis</i> , 2019, 32, 361-367.  | 0.7  | 7         |
| 96  | Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study. <i>PLoS ONE</i> , 2019, 14, e0213192.  | 1.1  | 32        |
| 97  | Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 87. | 0.7  | 12        |
| 98  | Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019, 380, 2295-2306.  | 13.9 | 3,760     |
| 99  | The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study. <i>Quality of Life Research</i> , 2019, 28, 2081-2090.   | 1.5  | 27        |
| 100 | Quality of life in caregivers compared with dialysis recipients: The CoACTIVE sub-study of the ACTIVE dialysis trial. <i>Nephrology</i> , 2019, 24, 1056-1063.   | 0.7  | 12        |
| 101 | Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2019, 171, 181.   | 2.0  | 108       |
| 102 | Inequities in the global representation of sites participating in large, multicentre dialysis trials: a systematic review. <i>BMJ Global Health</i> , 2019, 4, e001940.  | 2.0  | 7         |
| 103 | Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2229-2242.   | 3.0  | 93        |
| 104 | Varying Association of Extended Hours Dialysis with Quality of Life. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1751-1762.   | 2.2  | 13        |
| 105 | Cultivating Innovative Pragmatic Cluster-Randomized Registry Trials Embedded in Hemodialysis Care: Workshop Proceedings From 2018. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811989439.  | 0.6  | 7         |
| 106 | Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial. , 2019, 29, 276-284.   |      | 11        |
| 107 | Burden of Care and Quality of Life Among Caregivers for Adults Receiving Maintenance Dialysis: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2019, 73, 332-343.  | 2.1  | 84        |
| 108 | Kidney Health Australia - Caring for Australasians with Renal Impairment guideline recommendations for infection control for haemodialysis units. <i>Nephrology</i> , 2019, 24, 951-957.   | 0.7  | 5         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Effect of extended hours dialysis on sleep quality in a randomized trial. <i>Nephrology</i> , 2019, 24, 430-437.  | 0.7 | 7         |
| 110 | 1130-P: Temporal Trends in Pharmacotherapy for Diabetes. <i>Diabetes</i> , 2019, 68, 1130-P.  | 0.3 | 3         |
| 111 | 1129-P: Association between the Intensity of Diabetes Therapy, Achieved HbA1c, and Persistence. <i>Diabetes</i> , 2019, 68, .   | 0.3 | 0         |
| 112 | Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 805-814.                          | 2.2 | 65        |
| 113 | Design and methods of the REMOVAL-HD study: a tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HaemoDialysis patients. <i>BMC Nephrology</i> , 2018, 19, 89.              | 0.8 | 11        |
| 114 | Renal trials in diabetes need a platform: time for a global approach?. <i>Lancet Diabetes and Endocrinology,the</i> , 2018, 6, 356-358.   | 5.5 | 9         |
| 115 | Glucose lowering and the kidney: are all drug classes equal?. <i>Lancet Diabetes and Endocrinology,the</i> , 2018, 6, 835-837.  | 5.5 | 0         |
| 116 | Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. <i>Circulation</i> , 2018, 138, 1537-1550.  | 1.6 | 200       |
| 117 | Cardiovascular Outcomes Reported in Hemodialysis Trials. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2802-2810.  | 1.2 | 16        |
| 118 | Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease. <i>Diabetes</i> , 2018, 67, 258-OR.   | 0.3 | 0         |
| 119 | Muscle strength, mobility, quality of life and falls in patients on maintenance haemodialysis: A prospective study. <i>Nephrology</i> , 2017, 22, 220-227.  | 0.7 | 30        |
| 120 | A Trial of Extending Hemodialysis Hours and Quality of Life. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1898-1911.  | 3.0 | 62        |
| 121 | We Need to Talk about Depression and Dialysis: but What Questions Should We Ask, and Does Anyone Know the Answers?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 222-224. | 2.2 | 18        |
| 122 | Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet, The</i> , 2017, 390, 1888-1917.  | 6.3 | 662       |
| 123 | Scoring Risk Scores: Considerations Before Incorporating Clinical Risk Prediction Tools Into Your Practice. <i>American Journal of Kidney Diseases</i> , 2017, 69, 555-557.                                   | 2.1 | 8         |
| 124 | Closing the gap between evidence and practice in chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 114-121.  | 4.6 | 14        |
| 125 | Action plan for optimizing the design of clinical trials in chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 138-144.   | 4.6 | 19        |
| 126 | Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 432.  | 3.8 | 376       |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 368-375.  | 3.0 | 280       |
| 128 | Identifying and integrating patient and caregiver perspectives for clinical practice guidelines on the screening and management of infectious microorganisms in hemodialysis units. <i>Hemodialysis International</i> , 2017, 21, 213-223.  | 0.4 | 13        |
| 129 | The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017, 46, 462-472.   | 1.4 | 194       |
| 130 | Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0184398.   | 1.1 | 25        |
| 131 | Survival outcomes of supportive care <i>versus</i> dialysis therapies for elderly patients with end-stage kidney disease: A systematic review and meta-analysis. <i>Nephrology</i> , 2016, 21, 241-253.   | 0.7 | 93        |
| 132 | Prediction of 10-year vascular risk in patients with diabetes: the <i>ADON</i> risk score. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 289-294.   | 2.2 | 21        |
| 133 | Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. <i>The Cochrane Library</i> , 2016, 4, CD009631.   | 1.5 | 18        |
| 134 | Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. <i>BMJ</i> , The, 2016, 355, i5599.   | 3.0 | 25        |
| 135 | Interventions for lowering plasma homocysteine levels in dialysis patients. <i>The Cochrane Library</i> , 2016, 2016, CD004683.   | 1.5 | 21        |
| 136 | Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2888-2899.  | 1.2 | 171       |
| 137 | Effects of the Mediterranean Diet on Cardiovascular Outcomes—A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0159252.   | 1.1 | 145       |
| 138 | Interventions for lowering plasma homocysteine levels in kidney transplant recipients. <i>The Cochrane Library</i> , 2015, 2015, CD007910.  | 1.5 | 3         |
| 139 | Design and participant baseline characteristics of the <i>ACTIVE D</i> trial of Intensive Dialysis™: The <i>ACTIVE D</i> Study. <i>Nephrology</i> , 2015, 20, 257-265.  | 0.7 | 18        |
| 140 | Health-related quality of life in survivors of acute kidney injury: The <i>PROLONGED</i> study of the <i>RANDOMIZED</i> evaluation of <i>NORMAL</i> <i>versus</i> <i>...</i> <i>Augmented</i> <i>Level</i> <i>Replacement</i> <i>Therapy</i> study outcomes. <i>Nephrology</i> , 2015, 20, 492-498. | 0.7 | 26        |
| 141 | Renal effects of canagliflozin in type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2015, 31, 2219-2231.  | 0.9 | 49        |
| 142 | First Light After the Long Night: A Follow-up Report of the Randomized FHN Nocturnal Trial. <i>American Journal of Kidney Diseases</i> , 2015, 66, 379-382.   | 2.1 | 2         |
| 143 | A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. <i>American Journal of Kidney Diseases</i> , 2015, 65, 49-57.                 | 2.1 | 29        |
| 144 | Considerations of Nephrologists when Suggesting Dialysis in Elderly patients with Renal failure (CONSIDER): a discrete choice experiment. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2302-2309.   | 0.4 | 26        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Buttonhole Cannulation and Clinical Outcomes in a Home Hemodialysis Cohort and Systematic Review. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 110-119.  | 2.2 | 93        |
| 146 | Impact of Estimated GFR Reporting on Late Referral Rates and Practice Patterns for End-Stage Kidney Disease Patients: A Multilevel Logistic Regression Analysis Using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). <i>American Journal of Kidney Diseases</i> , 2014, 64, 359-366. | 2.1 | 31        |
| 147 | Effect of Hemodiafiltration or Hemofiltration Compared With Hemodialysis on Mortality and Cardiovascular Disease in Chronic Kidney Failure: A Systematic Review and Meta-analysis of Randomized Trials. <i>American Journal of Kidney Diseases</i> , 2014, 63, 968-978.   | 2.1 | 105       |
| 148 | Angiotensin-converting enzyme inhibitor usage and acute kidney injury: A secondary analysis of <sc>RENAL</sc> study outcomes. <i>Nephrology</i> , 2014, 19, 617-622.  | 0.7 | 16        |
| 149 | Acute Dialysis in Older Patients. , 2014, , 59-71.  |     | 0         |
| 150 | Non-tuberculous mycobacterial PD peritonitis in Australia. <i>International Urology and Nephrology</i> , 2013, 45, 1423-1428.   | 0.6 | 33        |
| 151 | Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2875-2888.   | 0.4 | 26        |
| 152 | Comparative efficacy of a team-led treatment protocol for the management of renal anaemia. <i>Nephrology</i> , 2013, 18, 649-654.   | 0.7 | 2         |
| 153 | Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2013, 34, 1807-1817.  | 1.0 | 156       |
| 154 | Antiplatelet Therapy to Prevent Hemodialysis Vascular Access Failure: Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2013, 61, 112-122.  | 2.1 | 81        |
| 155 | Effect of a Vascular Access Surveillance Program on Service Provision and Access Thrombosis. <i>Seminars in Dialysis</i> , 2013, 26, 361-365.   | 0.7 | 5         |
| 156 | Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. <i>American Journal of Kidney Diseases</i> , 2013, 61, 247-253.  | 2.1 | 52        |
| 157 | Tripterygium Preparations for the Treatment of CKD: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2013, 62, 515-530.  | 2.1 | 53        |
| 158 | Antiplatelet agents for chronic kidney disease. , 2013, , CD008834.   |     | 61        |
| 159 | mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 242-244.   | 0.4 | 12        |
| 160 | Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 3127-3127.   | 0.4 | 1         |
| 161 | Effects of Hemodiafiltration and High Flux Hemodialysis on Nerve Excitability in End-Stage Kidney Disease. <i>PLoS ONE</i> , 2013, 8, e59055.   | 1.1 | 18        |
| 162 | Survival of elderly dialysis patients is predicted by both patient and practice characteristics. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3581-3587.  | 0.4 | 75        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. <i>BMJ, The</i> , 2012, 344, e3533-e3533.  | 3.0 | 83        |
| 164 | Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2012, 156, 445.   | 2.0 | 179       |
| 165 | Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes. <i>American Journal of Kidney Diseases</i> , 2012, 60, 770-778.  | 2.1 | 110       |
| 166 | <i>Mycobacterium fortuitum</i> as a cause of peritoneal dialysis-associated peritonitis: case report and review of the literature. <i>BMC Nephrology</i> , 2012, 13, 35.   | 0.8 | 9         |
| 167 | If you can't comply with dialysis, how do you expect me to trust you with transplantation? Australian nephrologists' views on indigenous Australians' 'non-compliance' and their suitability for kidney transplantation. <i>International Journal for Equity in Health</i> , 2012, 11, 21. | 1.5 | 39        |
| 168 | Effects of Fibrates in Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2061-2071.   | 1.2 | 148       |
| 169 | Obstructive nephropathy secondary to a massive vesical calculus. <i>Internal Medicine Journal</i> , 2012, 42, 471-472.   | 0.5 | 0         |
| 170 | Benefits of exercise training in patients receiving haemodialysis: a systematic review and meta-analysis. <i>British Journal of Sports Medicine</i> , 2011, 45, 1165-1166.   | 3.1 | 7         |
| 171 | Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 265-278.   | 1.1 | 25        |
| 172 | Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2010, 153, 23.  | 2.0 | 297       |
| 173 | Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 852-858.  | 3.0 | 194       |
| 174 | Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2010, 56, 956-965.  | 1.2 | 171       |
| 175 | Systematic Review: Sodium Bicarbonate Treatment Regimens for the Prevention of Contrast-Induced Nephropathy. <i>Annals of Internal Medicine</i> , 2009, 151, 631.  | 2.0 | 156       |
| 176 | Indigenous people in Australia, Canada, New Zealand and the United States are less likely to receive renal transplantation. <i>Kidney International</i> , 2009, 76, 659-664.   | 2.6 | 103       |
| 177 | Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1813-1821.   | 3.0 | 787       |
| 178 | Proteinuria and Stroke: A Meta-analysis of Cohort Studies. <i>American Journal of Kidney Diseases</i> , 2009, 53, 417-425.   | 2.1 | 128       |
| 179 | Photopheresis therapy for problematic renal allograft rejection. <i>Journal of Clinical Apheresis</i> , 2009, 24, 161-169.   | 0.7 | 19        |
| 180 | Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2009, 373, 1009-1015.  | 6.3 | 384       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Cyclosporine Withdrawal Improves Long-Term Graft Survival in Renal Transplantation. Transplantation, 2009, 87, 1877-1883.  | 0.5 | 35        |
| 182 | Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney International, 2008, 73, 963-970.                                    | 2.6 | 40        |
| 183 | The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis. PLoS Medicine, 2008, 5, e207.   | 3.9 | 189       |
| 184 | Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering. Journal of the American Society of Nephrology: JASN, 2007, 18, 2766-2772. | 3.0 | 97        |
| 185 | Chemokine and toll-like receptor signaling in macrophage mediated islet xenograft rejection. Xenotransplantation, 2007, 14, 48-59.   | 1.6 | 23        |
| 186 | Trimming the fat: is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review. CKJ: Clinical Kidney Journal, 0, , .            | 1.4 | 0         |